106 related articles for article (PubMed ID: 26143926)
21. Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling.
Balla A; Tuymetova G; Toth B; Szentpetery Z; Zhao X; Knight ZA; Shokat K; Steinbach PJ; Balla T
Biochemistry; 2008 Feb; 47(6):1599-607. PubMed ID: 18205404
[TBL] [Abstract][Full Text] [Related]
22. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiological concentrations of amyloid beta proteins directly inhibit rat brain and recombinant human type II phosphatidylinositol 4-kinase activity.
Wu B; Kitagawa K; Zhang NY; Liu B; Inagaki C
J Neurochem; 2004 Dec; 91(5):1164-70. PubMed ID: 15569259
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of PI4K regulation and their involvement in viral replication.
McPhail JA; Burke JE
Traffic; 2023 Mar; 24(3):131-145. PubMed ID: 35579216
[TBL] [Abstract][Full Text] [Related]
26. Low-density crystal packing of human protein kinase CK2 catalytic subunit in complex with resorufin or other ligands: a tool to study the unique hinge-region plasticity of the enzyme without packing bias.
Klopffleisch K; Issinger OG; Niefind K
Acta Crystallogr D Biol Crystallogr; 2012 Aug; 68(Pt 8):883-92. PubMed ID: 22868753
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state.
Farenc C; Celie PH; Tensen CP; de Esch IJ; Siegal G
FEBS Lett; 2011 Nov; 585(22):3593-9. PubMed ID: 22036717
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
30. Role of PI3-kinase and PI4-kinase in actin polymerization during bovine sperm capacitation.
Etkovitz N; Rubinstein S; Daniel L; Breitbart H
Biol Reprod; 2007 Aug; 77(2):263-73. PubMed ID: 17494916
[TBL] [Abstract][Full Text] [Related]
31. Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
McPhail JA; Burke JE
Adv Exp Med Biol; 2020; 1274():203-222. PubMed ID: 32894512
[TBL] [Abstract][Full Text] [Related]
32. Crystal structure of human RIOK2 bound to a specific inhibitor.
Wang J; Varin T; Vieth M; Elkins JM
Open Biol; 2019 Apr; 9(4):190037. PubMed ID: 30991936
[TBL] [Abstract][Full Text] [Related]
33. Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors.
Avvaru BS; Wagner JM; Maresca A; Scozzafava A; Robbins AH; Supuran CT; McKenna R
Bioorg Med Chem Lett; 2010 Aug; 20(15):4376-81. PubMed ID: 20605094
[TBL] [Abstract][Full Text] [Related]
34. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
[TBL] [Abstract][Full Text] [Related]
35. Structural insights into enzyme regulation for inositol 1,4,5-trisphosphate 3-kinase B.
Chamberlain PP; Sandberg ML; Sauer K; Cooke MP; Lesley SA; Spraggon G
Biochemistry; 2005 Nov; 44(44):14486-93. PubMed ID: 16262249
[TBL] [Abstract][Full Text] [Related]
36. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
[TBL] [Abstract][Full Text] [Related]
37. Arabidopsis type-III phosphatidylinositol 4-kinases β1 and β2 are upstream of the phospholipase C pathway triggered by cold exposure.
Delage E; Ruelland E; Guillas I; Zachowski A; Puyaubert J
Plant Cell Physiol; 2012 Mar; 53(3):565-76. PubMed ID: 22318862
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of brain-type creatine kinase at 1.41 A resolution.
Eder M; Schlattner U; Becker A; Wallimann T; Kabsch W; Fritz-Wolf K
Protein Sci; 1999 Nov; 8(11):2258-69. PubMed ID: 10595529
[TBL] [Abstract][Full Text] [Related]
39. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
Patel SB; Cameron PM; O'Keefe SJ; Frantz-Wattley B; Thompson J; O'Neill EA; Tennis T; Liu L; Becker JW; Scapin G
Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):777-85. PubMed ID: 19622861
[TBL] [Abstract][Full Text] [Related]
40. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
